View Risk


Article data
Hamiel (2020)
SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults
10.1001/jama.2020.8189
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221856/

Results
Other
Childhood BCG vaccination (Present vs. Not present)
SARS COV-2 infection
Odds ratio: 1.219 (1.025-1.450) Univariate analysis

Study characteristics

Israel

Retrospective observational study

Registry

3007

Persons born from 1979 to 1981 (aged 39-41 years) with those born from 1983 to 1985 (aged 35-37 years). Patient with symptoms that could be compatible with COVID-19 (cough, dyspnea, fever).

50.8% male; mean age, 35 years The BCG vaccine was routinely administered to all newborns in Israel as part of the national immunization program between 1955 and 1982. Overall, the vaccine acceptance rate in Israel is high, with greater than 90% coverage. Since 1982, the vaccine has been administered only to immigrants from countries with high prevalence of tuberculosis.

Total

1 Month


Results

SARS COV-2 infection

660

Patient with symptoms that could be compatible with COVID-19 (cough, dyspnea, fever). Nasopharyngeal swabs were tested by real-time reverse transcriptase–polymerase chain reaction in approved laboratories

Other

Childhood BCG vaccination

BCG vaccine was routinely administered to all newborns in Israel as part of the national immunization program between 1955 and 1982. Since 1982, the vaccine has been administered only to immigrants from countries with high prevalence of tuberculosis.

Not present

299

1458

Present

361

1509

Odds ratio

1.219 (1.025-1.450)

No

Yes

No

Own calculated odds ratio. Stratified by age: individuals born during the 3 years before and 3 years after cessation of the universal BCG vaccine program.


Other information

Own calculated odds ratio. In conclusion, this study does not support the idea that BCG vaccination in childhood has a protective effect against COVID-19 in adulthood

Average

No

Go Back